Edition:
India

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

17.75USD
23 Feb 2018
Change (% chg)

$0.15 (+0.85%)
Prev Close
$17.60
Open
$17.70
Day's High
$17.80
Day's Low
$17.15
Volume
70,007
Avg. Vol
73,841
52-wk High
$17.98
52-wk Low
$6.35

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

31 Oct 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,528 +19.00
Eisai Co., Ltd (4523.T) ¥5,631 +61.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,611 +5.00
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Sanofi SA (SASY.PA) €65.05 +0.16
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00

Earnings vs. Estimates